Chemotherapy for ovarian cancer in the netherlands

A population based study on treatment patterns and outcomes

E. Houben, H. G. M. Van Haalen, W. Sparreboom, J. A. Overbeek, N.P.M. Ezendam, J. M. A. Pijnenborg, J. L. Severens, M. P. P. Van Herk-sukel

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Information on treatment patterns for ovarian cancer (oc) is limited. The aim of this study was to describe current patterns of chemotherapy and other systemic treatments for oc in the netherlands and evaluate survival outcomes following subsequent lines of treatment. Data from the eindhoven cancer registry, including on newly diagnosed cancer patients, were linked to the pharmo database network, including information on in- and out-patient drug use. Patients diagnosed with oc between January 2000 and december 2010 were selected. An algorithm was used to identify separate lines of treatment. Data were studied descriptively. Detailed data on systemic drug use were available for 261 patients (17%) with oc. In first line treatment, 87% of the patients (227/261) received platinum-based chemotherapy. Of the 161 patients receiving second-line treatment, 101 patients (63%) received platinum based chemotherapy. In third line, this was 51% (53/103). The median number of treatment lines received by patients was two (interquartile range 1-3), and eight or more lines of chemotherapy were identified for 12 patients. Median survival from diagnosis onwards was 47 months from the end of first line treatment, median survival was 32 months, and from the end of second line treatment, it was 14 months. Predominantly beyond second line treatment, there is much variety in treatment patterns with chemotherapy for oc. Although uncertainty remains regarding the desirability of this observed treatment variation, there seems a need for detailed clinical guidance, assuring that physicians can properly choose the most suitable treatment for each patient.
Original languageEnglish
Article number50
JournalMedical Oncology
Volume34
DOIs
Publication statusPublished - 1 Apr 2017

Fingerprint

Netherlands
Ovarian Neoplasms
Information Services
Pharmaceutical Preparations
Neoplasms
Outpatients
Databases
Physicians

Cite this

Houben, E., Van Haalen, H. G. M., Sparreboom, W., Overbeek, J. A., Ezendam, N. P. M., Pijnenborg, J. M. A., ... Van Herk-sukel, M. P. P. (2017). Chemotherapy for ovarian cancer in the netherlands: A population based study on treatment patterns and outcomes. Medical Oncology, 34, [50]. https://doi.org/10.1007/s12032-017-0901-x
Houben, E. ; Van Haalen, H. G. M. ; Sparreboom, W. ; Overbeek, J. A. ; Ezendam, N.P.M. ; Pijnenborg, J. M. A. ; Severens, J. L. ; Van Herk-sukel, M. P. P. / Chemotherapy for ovarian cancer in the netherlands : A population based study on treatment patterns and outcomes. In: Medical Oncology. 2017 ; Vol. 34.
@article{e40ecabba20942d286fb92bf1efc46ef,
title = "Chemotherapy for ovarian cancer in the netherlands: A population based study on treatment patterns and outcomes",
abstract = "Information on treatment patterns for ovarian cancer (oc) is limited. The aim of this study was to describe current patterns of chemotherapy and other systemic treatments for oc in the netherlands and evaluate survival outcomes following subsequent lines of treatment. Data from the eindhoven cancer registry, including on newly diagnosed cancer patients, were linked to the pharmo database network, including information on in- and out-patient drug use. Patients diagnosed with oc between January 2000 and december 2010 were selected. An algorithm was used to identify separate lines of treatment. Data were studied descriptively. Detailed data on systemic drug use were available for 261 patients (17{\%}) with oc. In first line treatment, 87{\%} of the patients (227/261) received platinum-based chemotherapy. Of the 161 patients receiving second-line treatment, 101 patients (63{\%}) received platinum based chemotherapy. In third line, this was 51{\%} (53/103). The median number of treatment lines received by patients was two (interquartile range 1-3), and eight or more lines of chemotherapy were identified for 12 patients. Median survival from diagnosis onwards was 47 months from the end of first line treatment, median survival was 32 months, and from the end of second line treatment, it was 14 months. Predominantly beyond second line treatment, there is much variety in treatment patterns with chemotherapy for oc. Although uncertainty remains regarding the desirability of this observed treatment variation, there seems a need for detailed clinical guidance, assuring that physicians can properly choose the most suitable treatment for each patient.",
author = "E. Houben and {Van Haalen}, {H. G. M.} and W. Sparreboom and Overbeek, {J. A.} and N.P.M. Ezendam and Pijnenborg, {J. M. A.} and Severens, {J. L.} and {Van Herk-sukel}, {M. P. P.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s12032-017-0901-x",
language = "English",
volume = "34",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",

}

Houben, E, Van Haalen, HGM, Sparreboom, W, Overbeek, JA, Ezendam, NPM, Pijnenborg, JMA, Severens, JL & Van Herk-sukel, MPP 2017, 'Chemotherapy for ovarian cancer in the netherlands: A population based study on treatment patterns and outcomes', Medical Oncology, vol. 34, 50. https://doi.org/10.1007/s12032-017-0901-x

Chemotherapy for ovarian cancer in the netherlands : A population based study on treatment patterns and outcomes. / Houben, E.; Van Haalen, H. G. M.; Sparreboom, W.; Overbeek, J. A.; Ezendam, N.P.M.; Pijnenborg, J. M. A.; Severens, J. L.; Van Herk-sukel, M. P. P.

In: Medical Oncology, Vol. 34, 50, 01.04.2017.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Chemotherapy for ovarian cancer in the netherlands

T2 - A population based study on treatment patterns and outcomes

AU - Houben, E.

AU - Van Haalen, H. G. M.

AU - Sparreboom, W.

AU - Overbeek, J. A.

AU - Ezendam, N.P.M.

AU - Pijnenborg, J. M. A.

AU - Severens, J. L.

AU - Van Herk-sukel, M. P. P.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Information on treatment patterns for ovarian cancer (oc) is limited. The aim of this study was to describe current patterns of chemotherapy and other systemic treatments for oc in the netherlands and evaluate survival outcomes following subsequent lines of treatment. Data from the eindhoven cancer registry, including on newly diagnosed cancer patients, were linked to the pharmo database network, including information on in- and out-patient drug use. Patients diagnosed with oc between January 2000 and december 2010 were selected. An algorithm was used to identify separate lines of treatment. Data were studied descriptively. Detailed data on systemic drug use were available for 261 patients (17%) with oc. In first line treatment, 87% of the patients (227/261) received platinum-based chemotherapy. Of the 161 patients receiving second-line treatment, 101 patients (63%) received platinum based chemotherapy. In third line, this was 51% (53/103). The median number of treatment lines received by patients was two (interquartile range 1-3), and eight or more lines of chemotherapy were identified for 12 patients. Median survival from diagnosis onwards was 47 months from the end of first line treatment, median survival was 32 months, and from the end of second line treatment, it was 14 months. Predominantly beyond second line treatment, there is much variety in treatment patterns with chemotherapy for oc. Although uncertainty remains regarding the desirability of this observed treatment variation, there seems a need for detailed clinical guidance, assuring that physicians can properly choose the most suitable treatment for each patient.

AB - Information on treatment patterns for ovarian cancer (oc) is limited. The aim of this study was to describe current patterns of chemotherapy and other systemic treatments for oc in the netherlands and evaluate survival outcomes following subsequent lines of treatment. Data from the eindhoven cancer registry, including on newly diagnosed cancer patients, were linked to the pharmo database network, including information on in- and out-patient drug use. Patients diagnosed with oc between January 2000 and december 2010 were selected. An algorithm was used to identify separate lines of treatment. Data were studied descriptively. Detailed data on systemic drug use were available for 261 patients (17%) with oc. In first line treatment, 87% of the patients (227/261) received platinum-based chemotherapy. Of the 161 patients receiving second-line treatment, 101 patients (63%) received platinum based chemotherapy. In third line, this was 51% (53/103). The median number of treatment lines received by patients was two (interquartile range 1-3), and eight or more lines of chemotherapy were identified for 12 patients. Median survival from diagnosis onwards was 47 months from the end of first line treatment, median survival was 32 months, and from the end of second line treatment, it was 14 months. Predominantly beyond second line treatment, there is much variety in treatment patterns with chemotherapy for oc. Although uncertainty remains regarding the desirability of this observed treatment variation, there seems a need for detailed clinical guidance, assuring that physicians can properly choose the most suitable treatment for each patient.

U2 - 10.1007/s12032-017-0901-x

DO - 10.1007/s12032-017-0901-x

M3 - Article

VL - 34

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

M1 - 50

ER -